|Dr. Mitchell H. Finer Ph.D.||Non-Exec. Chairman||126.65k||N/A||1959|
|Dr. Theodore T. Ashburn M.D., Ph.D.||Pres, CEO, Principal Financial Officer, Principal Accounting Officer & Director||760.13k||N/A||1967|
|Mr. Stephen W. Harbin||COO & Chief of Staff||815.09k||N/A||1959|
|Dr. Christophe Queva Ph.D.||Chief Scientific Officer & Sr. VP of Research||545.58k||N/A||1968|
|Brian Shea||Director of Legal Counsel||N/A||N/A||N/A|
|Dr. John Mayer Goldberg M.D.||Chief Medical Officer||N/A||N/A||1974|
|Mr. John McCabe M.B.A.||Advisor||N/A||N/A||1970|
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Oncorus, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 10. The pillar scores are Audit: 6; Board: 9; Shareholder Rights: 8; Compensation: 10.